Side-by-side · Research reference
AdipotidevsCJC-1295 (no DAC)
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BPhase 1HUMAN-REVIEWED15/51 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
CJC-1295 (no DAC)
Short-acting GHRH · No DAC variant
SQ · Pre-sleep · 1–2×/day
01Mechanism of Action
Parameter
Adipotide
CJC-1295 (no DAC)
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Pituitary GHRH receptorTeichman 2006
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
Yes — short pulse preserves somatostatin negative feedbackIonescu 2006
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006
Antibody development
—
Not reported in short-term studies
02Dosage Protocols
Parameter
Adipotide
CJC-1295 (no DAC)
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
—
Frequency
Not specified in available data
1–2× daily (pre-sleep ± morning)
Evidence basis
Preclinical animal models only
Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006Ionescu 2006
No-DAC variant is less studied directly; PK extrapolated from native GHRH.
Human data
None — no clinical trials reported
—
Lower / starter dose
—
50 mcg per dose
Duration
—
8–12 weeks on / 4 off (anecdotal)
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep + fasted preferred
Half-life
—
~30 minIonescu 2006
Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
CJC-1295 (no DAC)
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
CJC-1295 (no DAC)
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Injection site reaction
—
Erythema, mild pruritus
Flushing / headache
—
Common transient effect
Cortisol elevation
—
Minimal at standard doses
Prolactin elevation
—
Minimal
Glucose intolerance
—
Possible at high cumulative doses
IGF-1 elevation
—
Dose-dependent; monitor with chronic use
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
—
Avoid
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
CJC-1295 (no DAC)
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
CJC-1295 (no DAC)
- ·Untreated diabetes
- ·Severe insulin resistance
05Administration Protocol
Parameter
Adipotide
CJC-1295 (no DAC)
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Subcutaneous, abdomen or thigh. Rotate sites.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
Pre-sleep preferred. Often combined with ipamorelin in the same syringe.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Adipotide
— no documented stacks
CJC-1295 (no DAC)
+ Ipamorelin
StrongCJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.
- CJC-1295 (no DAC)
- 100 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition